Nicholas Saraceno, Editor

The agency will make its final decision surrounding the locally advanced or metastatic nonsquamous NSCLC drug —based on results from the TROPION-Lung01 Phase III trial—by Q4 2024.

The partnership revolves around meeting various agency standards and industry requirements pertaining to the drug development and manufacturing lifecycle.

The new seals include sustainable film material containing recyclate content of up to 90%.

The financial commitment features construction of new warehouses in Pennsylvania and North Carolina.

Scientists develop algorithms that can not only identify tumors that will respond well to chemotherapy, but which are also likely to resist treatment.

Analysis explores where drug prices are derived from, and whether a holistic societal approach can help determine these products’ true value.

Examination evaluates investigational stem cell interventions, including how the states have implemented their own policies when it comes to their uses.

Cohort study explores value-based insurance designs, while also determining how one’s place of residency can potentially play a role.

Researchers explore the proportion of approved drugs in the Canadian marketplace that utilize manufacturer-sponsored patient support programs, along with the types of medications that are more likely to do so.

Investigators examine the validity of phosphodiesterase type 5 inhibitors for erectile dysfunction, such as Viagra, being repurposed for the treatment of Alzheimer's disease.

A study investigates the effectiveness of bivalent mRNA COVID-19 vaccines against the Omicron variant among participants 5-17 years of age.

Trial for the treatment of ATTR-CM demonstrated an 81% absolute survival rate, along with an observed mean annual CVH frequency of 0.29.

Cohort study dives into whether low income subsidy losses are associated with disability status, age, and race and ethnicity.

A cohort study investigates the impact of Senate Bill 2994A and answers the question: does the repeal of school-entry nonmedical vaccination exemptions result in a rise in school vaccinations?

Pharma Commerce's new style is built off of the back of our new and improved editorial calendar.

Pharma Commerce travels to Orlando for a pulse-check on this fast-evolving landscape in patient care.

An analysis conducted by RAND Corporation determines that majority of new Rx medications are first sold in the United States before making their debut in other countries.

A dive into this market reveals that the latest numbers yield promising results—a global value of a worldwide $1.6 trillion—but it will continue to be attributed to past, present, and future healthcare spending.

Leading experts in the sector explore the value of third-party logistics providers when it comes to fortifying pharmaceutical supply chains.

Health Affairs study investigates the consequences of patient medication abandonment surrounding oral HIV pre-exposure prophylaxis.

New England Journal of Medicine study provides a breakdown of how hospitals—especially those that qualify for discounts under the federal 340B Drug Pricing Program—are able to make a profit off insurer pharmaceutical expenditures.

Cohort study aims to determine whether or not these regulatory changes in state government have helped reverse opioid mortality rates.

A non-randomized control trial investigates whether older adults with multiple chronic conditions can benefit by receiving more specialized services.

As technology continues to advance, investigators explore the legal protocol for how to handle AI-responsible injuries.

Dave DeJean provides his expert insight on lessons he’s learned from his plethora of time in the industry, along with an outlook on where the pharma supply chain stands in adhering to the Drug Supply Chain Security Act (DSCSA).

Study describes how a game theoretic model can successfully analyze how adoption of blockchain technology can reveal quality information.

Experts explore ways in which the financial sector refined the healthcare landscape, including its evolutions throughout the years.

In an interview with Pharma Commerce editor Nicholas Saraceno, Bill Roth, General Manager, Managing Partner, Blue Fin Group, discusses the changing role of PBMs and recent price structure overhauls.

In an interview with Pharma Commerce editor Nicholas Saraceno, Bill Roth, General Manager, Managing Partner, Blue Fin Group, discusses changes that will come with the pharma giant's new platform.

JAMA Health Forum details the DSCSA and stresses the value of protecting the pharmaceutical supply chain from adulterated products.